FIELD: medicine, pharmacology.
SUBSTANCE: invention relates to pharmaceutical composition for senile osteoporosis, post-menopausal osteoporosis, bone fractures, bone transplant, and osteopenia or male osteoporosis treatment, that include effective therapeutic quantity, in amount 0.01 mcg/kg/day to 10 mcg/kg/day of compound 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3, and effective therapeutic quantity, in amount 0.01 mcg/kg/day to 200 mcg/kg/day of selective estrogen receptor modulator, which bounds to estrogen receptor; the selective estrogen receptor modulator mentioned being chosen from the group comprising estrogen agonist, estrogen antagonist, or its pharmaceutically acceptable salt.
EFFECT: efficiency of medication is increased.
6 cl, 2 tbl, 1 ex
